A Phase I Platform Study of Rucaparib in Metastatic Castrate-resistant Prostate Cancer: Evaluation of Dose and Safety/tolerability of a Combination of Rucaparib with Androgen Receptor Inhibitors and/or Immunotherapy
|Effective start/end date||9/1/19 → 9/30/24|
- CLOVIS ONCOLOGY, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.